These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2589363)

  • 1. Safety and efficacy of intravenous ciprofloxacin in the treatment of selected infections.
    Abadie-Kemmerly S; Pankey GA
    Am J Med; 1989 Nov; 87(5A):213S-220S. PubMed ID: 2589363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
    Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH
    Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
    Modai J
    Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections.
    Peacock JE; Pegram PS; Weber SF; Leone PA
    Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intravenous ciprofloxacin in difficult-to-treat infections.
    Giamarellou H; Galanakis N
    Am J Med; 1987 Apr; 82(4A):346-51. PubMed ID: 3555059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Fass RJ; Plouffe JF; Russell JA
    Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime.
    Quintero-Perez NP; Andrade-Villaneuva JF; Leon-Garnica G; Bertin-Montano M; Rodriguez-Chagollan JJ; Rodriguez-Noriega E
    Am J Med; 1989 Nov; 87(5A):198S-201S. PubMed ID: 2686424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study.
    Villavicencio J; Asensio de Fernandez ME; Ramirez CA
    Am J Med; 1989 Nov; 87(5A):191S-194S. PubMed ID: 2686422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
    Sifuentes-Osornio J; Macías A; Amieva RI; Ramos A; Ruiz-Palacios GM
    Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous ciprofloxacin therapy in severe infections.
    Gudiol F; Cabellos C; Pallares R; Linares J; Ariza J
    Am J Med; 1989 Nov; 87(5A):221S-224S. PubMed ID: 2589364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Levine DP; McNeil P; Lerner SA
    Am J Med; 1989 Nov; 87(5A):160S-163S. PubMed ID: 2686416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of serious infections with intravenous ciprofloxacin.
    Scully BE; Neu HC
    Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
    Neu HC; Davidson S; Briones F
    Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
    Brown AE; Smith G
    Am J Med; 1989 Nov; 87(5A):266S-268S. PubMed ID: 2589376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
    Gaut PL; Carron WC; Ching WT; Meyer RD
    Am J Med; 1989 Nov; 87(5A):169S-175S. PubMed ID: 2686417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
    Davis C
    Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime.
    Parish LC; Asper R
    Am J Med; 1987 Apr; 82(4A):227-9. PubMed ID: 3555041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
    Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of intravenous ciprofloxacin. A review.
    Arcieri GM; Becker N; Esposito B; Griffith E; Heyd A; Neumann C; O'Brien B; Schacht P
    Am J Med; 1989 Nov; 87(5A):92S-97S. PubMed ID: 2686431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
    J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.